KYNB (Kyntra Bio) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KYNB Kyntra Bio Inc KYNB
51 GF Score
Price $6.96
GF Value $5.59
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio Net Loan?

Net Loan only applies to banks and insurance companies.

KYNB
51GF Score
Kyntra Bio Inc KYNB
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kyntra Bio (KYNB) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of $6.96 is trading 24.5% above its estimated GF Value™ of $5.59. GuruFocus considers Kyntra Bio to be Modestly Overvalued.

Key valuation signals for KYNB:

  • Net Loan:
  • GF Value™: $5.59 vs. price of $6.96 (24.5% above fair value)
  • GF Score™: 51/100 with 8 warning signs

No single metric tells the full story. See the KYNB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyntra Bio Business Description

Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
51GF Score

Get the complete analysis for KYNB

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.96
Price
$5.59
GF Value